Millennium Management
GLUE icon

Millennium Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Millennium Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.15M Buy
191,382
+87,410
+84% +$1.67M ﹤0.01% 3428
2025
Q4 		$1.63M Sell
103,972
-340,967
-77% -$4.59M ﹤0.01% 4111
2025
Q3 		$3.3M Buy
444,939
+380,308
+588% +$2.01M ﹤0.01% 3557
2025
Q2 		$291K Sell
64,631
-265,836
-80% -$1.19M ﹤0.01% 5205
2025
Q1 		$1.53M Buy
330,467
+284,097
+613% +$1.74M ﹤0.01% 4020
2024
Q4 		$322K Buy
46,370
+15,749
+51% +$118K ﹤0.01% 5035
2024
Q3 		$162K Buy
30,621
+9,693
+46% +$48.9K ﹤0.01% 5498
2024
Q2 		$78.3K Sell
20,928
-129,097
-86% -$658K ﹤0.01% 5349
2024
Q1 		$1.06M Buy
150,025
+82,746
+123% +$491K ﹤0.01% 4244
2023
Q4 		$380K Buy
+67,279
New +$264K ﹤0.01% 4820
2023
Q2 		– Sell
-117,094
Closed -$912K – 6314
2023
Q1 		$912K Sell
117,094
-276,056
-70% -$1.92M ﹤0.01% 4179
2022
Q4 		$2.99M Buy
393,150
+367,221
+1,416% +$3.06M ﹤0.01% 3216
2022
Q3 		$212K Buy
25,929
+8,526
+49% +$78.3K ﹤0.01% 5620
2022
Q2 		$168K Buy
+17,403
New +$175K ﹤0.01% 5718
2021
Q4 		– Sell
-175,445
Closed -$3.91M – 7008
2021
Q3 		$3.91M Sell
175,445
-59,657
-25% -$1.71M ﹤0.01% 3154
2021
Q2 		$5.34M Buy
+235,102
New +$4.79M ﹤0.01% 2671

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Millennium Management's GLUE Position: Q1 2026 in Review

Millennium Management increased its Monte Rosa Therapeutics (GLUE) stake by 84% in Q1 2026, buying an estimated $1.67M and bringing the position to 191,382 shares worth $3.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3428.

Millennium Management first reported a position in GLUE in Q2 2021 and has held it in 16 quarters since. The position peaked at $5.34M in Q2 2021. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Millennium Management held 191,382 shares of Monte Rosa Therapeutics worth $3.15M as of Q1 2026.
  • Millennium Management bought 87,410 Monte Rosa Therapeutics shares in Q1 2026, an estimated $1.67M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3428 holding.
  • Millennium Management first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • Millennium Management's Monte Rosa Therapeutics position peaked at $5.34M in Q2 2021.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.